Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I

• Published in: Journal of the American College of Cardiology 2010-05, Vol.55 (19), p.2118-2124
• Main Authors: Bonaca, Marc, MD, Scirica, Benjamin, MD, MPH, Sabatine, Marc, MD, MPH, Dalby, Anthony, MD, Spinar, Jindrich, MD, Murphy, Sabina A., MPH, Jarolim, Peter, MD, PhD, Braunwald, Eugene, MD, Morrow, David A., MD, MPH
• Format: Article
• Language: English
• Subjects: Acetanilides - therapeutic use; ACS; acute coronary syndrome; Acute Coronary Syndrome - blood; Acute Coronary Syndrome - diagnosis; Acute Coronary Syndrome - mortality; Acute coronary syndromes; Aged; Biomarkers; Biomarkers - blood; Cardiology; Cardiovascular; Confidence intervals; Diabetes; Enzyme Inhibitors - therapeutic use; Female; Follow-Up Studies; Heart attacks; Heart failure; Hospitalization; Humans; Internal Medicine; Ischemia; Male; Middle Aged; Myocardial Infarction - blood; Myocardial Infarction - diagnosis; Myocardial Infarction - epidemiology; Piperazines - therapeutic use; Predictive Value of Tests; Prognosis; Prospective Studies; Ranolazine; Risk assessment; Risk Factors; sensitive; Statistical methods; Studies; troponin; Troponin I - blood
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2010.01.044

Objectives The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS). Background Recent enhancements in troponin assays have enabled resolution of the 99th percentile reference limit at progressively lower concentrations. However, the clinical significance of low-level increases with sensitive assays is still debated. Methods We measured cTnI using a sensitive assay (TnI-Ultra, Siemens Healthcare Diagnostics, Deerfield, Illinois) at baseline in 4,513 patients with non–ST-segment elevation ACS randomly assigned to ranolazine or placebo. We applied decision limits at the 99th percentile reference limit (0.04 μg/l), the cut point of the predecessor assay (0.1 μg/l), and 1 equivalent to elevation of creatine kinase–myocardial band (1.5 ng/ml). Results Patients with baseline cTnI ≥0.04 μg/l (n = 2,924) were at higher risk of death/myocardial infarction (MI) at 30 days than were patients with a negative cTnI (6.1% vs. 2.0%, p < 0.001). After adjusting for the TIMI (Thrombolysis In Myocardial Infarction) risk score, cTnI ≥0.04 μg/l was associated with a 3-fold (95% confidence interval: 2.0 to 4.4, p < 0.001) higher risk of death/MI at 30 days. Moreover, patients with low-level increases (0.04 μg/l to